RxDoctor Payments Data

Aruna Krishnaswamy, MD

Internal Medicine · Westminster, CANPI 1548479140

Payments from drug & device makers

$2,339in general payments, 2019–2025

Across 102 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$469
  • Lilly USA, LLC$288
  • Madrigal Pharmaceuticals$239
  • Astellas Pharma US Inc$195
  • Novartis$173
  • Amgen$169
  • plus $806 from 19 others

What the payments were for

  • Food & beverage$2,339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,339 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$34,226
Medicare patients
134
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$107,598
EliquisApixaban89$80,534
JanuviaSitagliptin Phosphate88$73,660
OzempicSemaglutide54$56,916
XareltoRivaroxaban16$20,378
TrulicityDulaglutide14$19,555
SynjardyEmpagliflozin/Metformin Hcl11$13,036
FarxigaDapagliflozin Propanediol12$10,502
LinzessLinaclotide11$10,485
Atrovent HfaIpratropium Bromide12$5,938
Atorvastatin Calcium672$5,197
Fluticasone Propionate HfaFluticasone Propionate21$4,353
AlogliptinAlogliptin Benzoate15$3,388
Losartan Potassium339$2,764
Arnuity ElliptaFluticasone Furoate13$2,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$80,53489 claims
MerckJanuvia$63$73,66088 claims
Novo NordiskOzempic$150$56,91654 claims
Johnson & JohnsonXarelto$19$20,37816 claims
Lilly USA, LLCTrulicity$288$19,55514 claims
AstraZenecaFarxiga$50$10,50212 claims
AbbVieLinzess$38$10,48511 claims
GSKArnuity Ellipta$43$2,65713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →